Skip to content

Geron GERN Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
Tango Therapeutics logo
Tango TherapeuticsTNGX
Exelixis logo
ExelixisEXEL
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Biogen logo
BiogenBIIB
GRAIL, Inc. logo
GRAIL, Inc.GRAL

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's unrealized gains on investments?
Geron (GERN) reported unrealized gains on investments of $34K in Q1 2026.
How has Geron's unrealized gains on investments changed year-over-year?
Geron's unrealized gains on investments decreased by 90.9% year-over-year, from $373K to $34K.